Concentrated hydrogel microcapsule composition and surgical dressing thereof

FIELD: medicine.

SUBSTANCE: what is described is hydrogel composition containing sodium acrylate, a linking agent, biologically active substances, polyvinyl pyrrolidone, glycerol, propanediol, water, a catalyst agent and a radical polymerisation indicator in the following proportions, wt %: sodium acrylate 2.0-10.0, catalyst agent 0.045-0.48, linking agent 0.195-0.21, radical polymerisation indicator 0.045-0.06, glycerol 4.5-7.5, propanediol 3.0-10.5, biologically active substances 0-1.5, polyvinyl pyrrolidone 0.3-1.5, water - the rest. What is described is a surgical dressing containing a carrier with the hydrogel composition applied thereon.

EFFECT: higher efficacy of the hydrogel composition and surgical dressing thereof, lower labour intensity of the method for preparing the above composition.

10 cl, 1 tbl, 2 ex

 

The group of inventions relates to medicine, namely to pharmaceutical compositions and medical devices for the treatment (healing) wounds of different etiologies, including pressure ulcers, diabetic foot, venous ulcers, herpes lesions on the lips and the skin of people, burns of any degree of severity, for preventing the formation of stitches, post-burn scars and keloids and may find application in surgery, dermatology, obstetrics, gynecology, and otolaryngology for the treatment of inflammatory processes of the soft tissues.

Known (patent No. 2157243 C1 IPC7A6L 15/22) adopted for the prototype objects of the claimed group of inventions hydrogel composition and the dressing tool out of it for the treatment of wounds of various etiologies. Known hydrogel composition contains acrylamide and/or sodium acrylate, a crosslinking agent, biologically active substances (BAS), polyvinylpyrrolidone, glycerin, propandiol and water in the following ratio, wt.%:

Propandiol
Acrylamide0,005-4,8
Sodium acrylate0-4,5
A crosslinking agent0,015-0,16
Glycerin1.5 to 2.5
1,0-3,5
Biologically active substances0-1,5
Polyvinylpyrrolidone0,1-0,5
WaterRest

The disadvantages of the known pharmaceutical compositions and, accordingly, the dressing tools based on it, preventing people from getting below the specified technical result are: the presence in its composition (one of the alternatives) highly toxic substances (acrylamide), and low concentration of sodium acrylate.

Objective of the claimed group of inventions is the creation of an effective pharmaceutical compositions for the treatment of wounds of various etiologies and superior and perfect in structure and properties of medical devices with high biological activity.

Unified technical result to be obtained by the implementation and use of a group of inventions is to improve the efficiency of hydrogel compositions and dressing tools based on it, reducing the labor intensity of the production method of the specified composition.

This technical result for object "hydrogel composition" is due to the fact that in the hydrogel composition, tereasa sodium acrylate, a crosslinking agent, biologically active substances, polyvinylpyrrolidone, glycerin, propandiol and water, a crosslinking agent together with the catalyst and the initiator of radical polymerization is part of the complex catalyst in the following ratio, wt.%:

sodium acrylate2,0-10,0
complex catalyst0,045-0,48
glycerin4,5-7,5
propandiol3,0-10,5
biologically active substances0-1,5
polyvinylpyrrolidone0,3-1,5
waterrest

The above common effect for object ' dressing tool is due to the fact that the dressing tool includes a substrate coated with hydrogel composition containing a crosslinking agent, catalyst and initiator of radical polymerization in the complex catalyst, sodium acrylate, biologically active substances, glycerol, polyvinylpyrrolidone, propandiol and water when SL is blowing ratio of components wt.%:

sodium acrylate2,0-10,0
complex catalyst0,045-0,48
glycerin4,5-7,5
propandiol3,0-10,5
biologically active substances0-1,5
polyvinylpyrrolidone0,3-1,5
waterrest

The exception to the composition of the hydrogel composition (prototype) acrylamide, which is a very toxic substance, lets talk about the environmental improvement (additional technical result) method of its manufacture (when using acrylamide, remnants of it are released into the environment with wastewater from washing dishes and equipment for obtaining hydrogel), and enhancing the purity (excludes the ingress of residual toxic monomers of acrylamide in the hydrogel) of the final hydrogel composition. In the final composition sodium acrylate is in the form of a polyacrylate, Pets presence of small amounts of monomer is sodium acrylate, which is not a Ki is a toxic substance.

Increasing the concentration of sodium acrylate to 10% wt.% leads to a more complete polymerization, which eliminates stage washing of the gel and reduce the consumption of distilled water (save water) and the amount of waste water (reduction of waste). At small values (less than 2%) of monomer concentration and the concentration of crosslinking agent polyacrylate gel cannot be considered rigid regular spatial lattice. Rather, it is the long strands of polymer, only at certain points randomly interconnected. The degree of crosslinking of such a gel is small, the viscosity is low. With an increase (10%) concentrations of monomer and, correspondingly, the concentration of crosslinking agent, the degree of crosslinking of the polymer composition increases, the polymer gel is more regular and orderly patterns.

Glycerin and propandiol in this hydrogel compositions are plasticizers. Glycerin is used to soften the composition, protection from evaporation of the liquid, the improvement dissolving drugs, as an antiseptic. The use of propane diol is also due to the ability to soften the surface layer of the epidermis and transport of hydrophobic molecules and hydrophilic biologically active substances into the cells. Propandiol additionally possesses bactericidal with what properties.

Polyvinylpyrrolidone is used as a copolymer in the production of polymeric materials, and is introduced to prolong the action of drugs.

This composition comprises a single phase aqueous colloid, in which the polymer (sodium acrylate) absorbs water or buffer solution. The hydrogel contains multiple links, where each link represents a molecular cross-linked hydrogel. The degree of crosslinking of the polymer effect on some functional properties of the hydrogel, including its ability to absorb wound fluid, and it can be adjusted by varying the concentration of crosslinking agent in the composition of complex catalyst, changing the reaction conditions, etc.

As a result of polymerization of sodium acrylate obtained from the long thread polyacrylate. Thread polyacrylate are chaotically. These strands are covalently linked ("stitched") between the bridges N,N-methylene-bis-acrylamide (crosslinking agent). Get the irregular shape of the pores of the spatial grid, the average size of which is determined by the frequency of the location of the crosslinks and the concentration of the main threads of the polyacrylate. Education dimensional grid of the gel occurs in the solution of the selected buffer, which thereby fills all the pores of the gel.

Components of complex catalyst in addition to the cross-linking agent are catalysis is the PR and initiator of radical polymerization.

As accelerating the polymerization catalyst used is N,N,N,N-tetramethylethylenediamine, and the initiator of radical polymerization (initiated the beginning of the polymerization process) is ammonium persulfate. These two substances are used in small quantities as stimulating supplements.

Hydrogel composition obtained by polymerization of a hydrophilic monomer (sodium acrylate) in the presence of a complex catalyst containing in its composition:

N,N,N,N-tetramethylethylenediamine in the number of 0.045 and 0.06%,

N,N-methylene-bis-acrylamide in the amount of € 0.195-0,21%,

the ammonia persulfate in an amount of 0.045 and 0.06%,

As biologically active substances hydrogel composition may contain a preservative (for example, Lodovico) and/or an antibiotic (e.g. gentamicin sulfate), proteolytic enzymes (e.g., turrilites); local anesthetic (for example, amylocaine) and/or antiseptic.

When this selection and the ratio of the initial components of the hydrogel is more ordered mesh structure in comparison with the known composition (patent No. 2157243), thereby increasing the absorption capacity and the best retention gel wound exudate.

The biological activity of the composition was evaluated by two parameters: antimicrobial activity and analgesic effect.

Definition is of antimicrobial activity was performed against gram-positive microflora Staphylococus aureus, gram-negative microflora Ps. Aeruginosa.

For evaluation of analgesic effect was used developed in the Institute of surgery. A.V. Vishnevsky RAMS evaluation method of experimental pain study data characteristics of the electroencephalogram.

Data on the biological activity of the applied compositions are shown in table 1.

The method of obtaining the claimed hydrogel composition consists of the following steps.

In a glass bowl with bidistilled water with constant stirring contribute sodium acrylate and N,N-methylene-bis-acrylamide. To the resulting mixture add the glycerin and propandiol. The mixture is then vacuum to remove dissolved air. The pressure was raised to atmospheric and enter the remaining components of the complex polymerization catalyst (ammonium persulfate and N,N,N,N-tetramethylethylenediamine) with the formation of biologically inert hydrophilic polymer (gel-like crosslinked material, a hydrogel). The resulting hydrogel is dispersed (by punching through the vacuum sieve) to obtain microcapsules and saturate water with dissolved drug to the status of an elastic gel. Water-soluble drug, thus, is included in polyacrylate gel. The result is a fine particle system of polim the RA, saturated BAS.

This method of introducing water-soluble drug has a shared meaning and a) does not limit the range of the used water-soluble biologically active substances, b) provides the prolongation of action of biologically active substances due to the slower release of the individual polymer particles in comparison with the solution. Due to the prolonged action of biologically active substances increases the residence time of the hydrogel or the dressing tool based on the wound surface with the provision of therapeutic effects, which gives the possibility to reduce the number of dressing changes and the treatment of wounds.

The hydrogel can be placed in a separate sterile bottle, vessel, vial, vial, tube, applied to the substrate, the applicator etc.

As evidence, confirming the ability of the invention to provide the above technical result, below are examples of hydrogel compositions of different composition.

Example 1

Hydrogel microcapsules polymer composition comprising sodium acrylate, complex catalyst, biologically active substances, polyvinylpyrrolidone, glycerin, propandiol and water in the following ratio, wt.%:

Sodium acrylate 3,0

Complex catalyst:

N,N-methylene-bis-acrylamideof € 0.195
N,N,N,N-tetramethylethylenediamine0,045
the ammonia persulfate0,045
Glycerin4,5
Propandiol3,0

BAS:

Yodovidon1,0
Anakain1,0
Polyvinylpyrrolidone0,3
WaterRest

The composition described in example 1 is used in the treatment of wound surfaces by applying a gel to the substrate, i.e. in the form of a bandage.

Example 2

Hydrogel microcapsules polymer composition comprising sodium acrylate, complex catalyst, biologically active substances, polyvinylpyrrolidone, glycerin, propandiol and water in the following ratio, wt.%:

Sodium acrylate8,0

Complex catalyst:

N,N-methylene-bis-acrylamide0,21
N,N,N,N-tetramethylethylenediamine0,06
the ammonia persulfate0,06
Glycerin7,5
Propandiol10,5

BAS:

Miramistin0,01
Anakain1,0
Polyvinylpyrrolidone1,5
WaterRest

The composition described in example 2 is used in the treatment of wound surfaces by applying the gel directly on the wound surface, since it is almost impossible to get the bandage on the basis of the substrate due to the relatively high viscosity of the composition.

Various ways of storing and using these compositions.

Hydrogel composition can contain, in separate sterile bottle, with the Ude, the bubble tube and apply directly on the treated wound surface or substrate, the applicator and other Ways of applying gel: through the applicator tube (nozzle), with a spatula, using the applicator, applied on the reinforcing base, manually by applying to the wound or any other known means.

The substrate may be perforated substrate of natural and/or synthetic material, including reinforcing mesh or cotton gauze, mesh material made of natural and/or synthetic fibers.

The effectiveness of the dressing tool containing substrate with a hydrogel composition of the claimed composition, is determined by the efficiency of the specified composition.

/tr>
Table 1
No.Biologically active additives and their amountBiological activity
1Yodovidon 10% + Anakain 1%St. Aureus 2-3 mm
Anesthesia 2-5 hours
2Yodovidon 10%St. Aureus 2-3 mm
3Miramistin 0,1% + Anakain 1,5%St. Aureus 2-5 mm
Anesthesia 2-5 hours
4Miramistin 0,1%St. Aureus 2-5 mm
5Gentamicin sulfate 0,1% + Anakain 1,5%St. Aureus 2-5 mm
Ps. The Aer. 6-7 mm
Anesthesia 2-5 hours
6Gentamicin sulfate 0,1%St. Aureus 2-5 mm
Ps. Aer.6-7 mm
7Chlorhexidine 0,5% + Anakain 1%St. Aureus 7-8 mm
Ps. Aer.3-5 mm
Anesthesia 2-5 hours
8Chlorhexidine 0,5% St. Aureus 7-8 mm
Ps. The Aer. 3-5 mm
9Dioxidine 2% + Terrilian 100 PE/gSt. Aureus 8-11 mm
Ps. The Aer. 12-15 mm
10Dioxidine 2% + Anakain 2,5%St. Aureus 8-11 mm
Ps. The Aer. 12-15 mm
Anesthesia 5-8 hour
11Dioxidine 2%St. Aureus 8-11 mm
Ps. The Aer. 12-15 mm
11Lincomycin hydrochloride 2%St. Aureus 8-11 mm
12Lincomycin hydrochloride 2% + Anakain 2,5%St. Aureus 2-5 mm
Anesthesia 5-8 hour
13The katapola 1%+ Trimekain 1% St. Aureus 2-4 mm
Anesthesia 4-5 hour
14The katapola 1%St. Aureus 2-4 mm

15Levomycetin 1% + Amylocaine 2%St. Aureus 9-10 mm
Ps. The Aer. 3-4 mm
Anesthesia 5-8 hour
16Levomycetin 1%St. Aureus 9-10 mm
Ps. The Aer. 3-4 mm
17Furagin potassium 0,5% + lidocaine 0,25%St. Aureus 5-7 mm
Anesthesia 1-2 hours
18Furagin potassium 0,5%St. Aureus 5-7 mm
19Chlorhexidine 0,5% + anakain 1%St. Aureus 78 mm
Ps. The Aer. 3-5 mm
Anesthesia 2-5 hours
20Chlorhexidine 0,5%St. Aureus 7-8 mm
Ps. The Aer. 3-5 mm
21TerrilianSt. Aureus 2-4 mm

1. Hydrogel composition for the treatment of wounds of various etiologies, containing sodium acrylate, a crosslinking agent, biologically active substances, polyvinylpyrrolidone, glycerin, propandiol and water, characterized in that it further comprises the catalyst N,N,N,N-tetramethylethylenediamine, initiator of radical polymerization of the ammonium persulfate, and as cross-linking agent used is N,N-methylene-bis-acrylamide in the following ratio, wt.%:

the catalyst N,N,N,N-tetramethylethylenediamine0,045-0,06
a crosslinking agent N,N-methylene-bis-acrylamideof € 0.195-0,21
the initiator of radical polymerization of MMA is in the persulfate 0,045-0,06
sodium acrylate2,0-10,0
glycerin4,5-7,5
propandiol3,0-10,5
biologically active substances0-1,5
polyvinylpyrrolidone0,3-1,5
waterrest

2. Hydrogel composition according to claim 1, characterized in that the biologically active substance contains antiseptic and/or antibiotic.

3. Hydrogel composition according to claim 1, characterized in that the biologically active substance contains proteolytic enzymes.

4. Hydrogel composition according to claim 1, characterized in that the biologically active substance contains a local anesthetic and/or antiseptic.

5. The dressing tool, characterized in that it comprises a substrate coated with hydrogel composition containing sodium acrylate, a crosslinking agent N,N-methylene-bis-acrylamide, the catalyst N,N,N,N-tetramethylethylenediamine, initiator of radical polymerization of the ammonium persulfate, biologically active substances, glycerol, polyvinylpyrrolidone, propand the ol and water in the following ratio of components, wt.%:

the catalyst N,N,N,N-tetramethylethylenediamine0,045-0,06
a crosslinking agent N,N-methylene-bis-acrylamideof € 0.195-0,21
the initiator of radical polymerization, the ammonium persulfate0,045-0,06
sodium acrylate2,0-10,0
glycerin4,5-7,5
propandiol3,0-10,5
biologically active substances0-1,5
polyvinylpyrrolidone0,3-1,5

waterrest

6. The dressing tool according to claim 5, characterized in that the substrate is used reinforcing mesh or cotton gauze.

7. The dressing tool according to claim 5, characterized in that the substrate is used perforated substrate of natural and/or synthetic material.

8. The dressing tool according to claim 5, characterized in that the biologically active washes the VA contains antiseptic and/or antibiotic.

9. The dressing tool according to claim 5, characterized in that the biologically active substance contains proteolytic enzymes.

10. The dressing tool according to claim 5, characterized in that the biologically active substance contains an anaesthetic and/or antiseptic.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an immunomodulatory composition for injection into a mammal. The immunomodulatory composition for injection into a mammal containing a hydrolysate prepared by acid and/or enzymatic hydrolysis of one or more bioresources specified in a group consisting of bivalve molluscs, annelids, leeches, and water taken in certain proportions. A method for preparing the immunomodulatory composition for injection into a mammal. A method of treating a pathological condition in a mammal in need thereof involving the injections of the immunomodulatory composition into the above mammal. Using the composition for normalising metabolism into the mammal in need thereof.

EFFECT: composition enables extending the range of products with immunomodulatory activity for injections.

19 cl, 7 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: waste skin is incised on the periphery of the wound. The incised skin is prepared from the residual subcutaneous fat and milled to fragments having an area of 1-2 mm2. A dermal matrix made of dead donor's tissue is simulated after the wound shape. The dermal matrix (DM) is perforated to create traumatic discharge outflow tracts and laid on a wound bed so that to form a diastasis between perforation edges. Patient's waste skin fragments are introduced into the perforations in a staggered order. The wound is closed with a sterile gauze dressing. The other invention is allogenic mesenchymal multipotent stromal cell (MMSC) transplantation onto the wound bed in the form of the suspension by means of injections at a depth of 0.1-0.3 mm at a rate of 10 injections per 1 cm2. A volume of each injection makes 0.05-0.1 ml. The dermal matrix made of dead donor's tissue is simulated after the wound shape. That is perforated to form the traumatic discharge outflow tracts and laid on the wound bed. The wound is closed with the sterile gauze dressing. The effect is ensured by using the DM as an optimum biocompatible cell carrier and creating a required micromedium in the wound, stimulating the regeneration processes ensured by a combination with the homogenised autologous skin or allogenic MMSC injections into the wound.

EFFECT: inventions provide optimising skin and soft tissue wound healing ensured by stimulating the regeneration processes by means of stromal cells, including allo- and auto-MMSC and resident stem cells.

5 cl, 2 ex

FIELD: medicine.

SUBSTANCE: combined graft (CG) represents a dermal matrix (DM) prepared of a donor layer with self-specific multipotent mesenchymal stromal cells (MMSC) colonised on the surface thereof to the number of not less than 750-1500 thousand per 1 cm2. The group of inventions also refers to a method for preparing the combined graft involving bone marrow sampling from the patient, preparing a MMSC culture, applying a MMSC suspension in the concentration of not less than 1 million/ml on the DM surface at 1 million MMSC per 5 cm2 of the DM.

EFFECT: skin and soft tissue wound healing by accelerating regeneration processes.

11 cl

FIELD: medicine.

SUBSTANCE: method for local wound healing involving using a biological dressing which is applied on a wound surface. The biological dressing contains a polymer base of a hydrophobic perforated silicone film coated with a layer of human collagen type I and human diploid cells. The biological dressing is square-shaped and contains the diploid cells in the form of the characterised live cells of M-20 human fibroblasts at the level of passages No. 20-33 in the form of cell monolayers of 70-80% saturation density prepared at a starting density of (4-5)×104 cells per 1 cm2 of the dressing and culturing in a nutrient medium with fibrinolytically active plasma added. Vast injuries may require placing a desired number of the line-on-line dressings on the wound surface. Preferentially, the dressing is applied from the 1st-2nd post-injury day.

EFFECT: improving repair processed in the wound and reducing time of healing.

4 cl, 4 ex, 1 tbl, 3 dwg

Medical glue // 2526188

FIELD: medicine.

SUBSTANCE: medical glue "Neosulphacrylate" contains, wt.p.: ethyl-α-cyanacrylate 76.5-85.0, 3-methacrylcarboxysulpholane 9.0-12.5, decylmetacrylate 6.0-11.0.

EFFECT: glue extends an assortment of compositions of the stated purpose, possesses improved organoleptic properties, increased adhesion and reduced neurotoxicity in tissue gluing, provides an increase of anti-inflammatory action with preservation of such physic-chemical characteristics as rupture strength and elasticity at the level of its prototype.

2 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely to an ointment for burns, folliculitis, furunculosis, vasculitis treatment and wound healing. The ointment for burns, folliculitis, furunculosis, vasculitis treatment and wound healing containing: bees wax, line seed oil, kerosene and visceral fat of pig taken in certain proportions.

EFFECT: ointment possesses a biostimulating effect, reduces the wound healing time with no post-therapeutic cicatrisation with good fixation, uniform distribution on the skin surface and ease of use.

9 dwg, 9 ex

FIELD: medicine.

SUBSTANCE: experimental wound is cleaned daily, first with normal saline (NaCl), and then coated with modified montmorillonite clay containing 0.1 to 4.35 wt % of silver. The preparation is introduced into the wound in an amount of 0.1 g per a wound of 1.5 cm in diameter.

EFFECT: higher rate of septic wound healing.

3 tbl, 3 dwg

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to cosmetology, and can be used for treatment of skin aging. For this purpose, used is a medication, which contains a basic fibroblast growth factor (bFGF) as a single active ingredient, which is introduced intracutaneously or subcutaneously into the place of a scar or into the surrounding region, for instance, a keloid, a hypertrophic scar and a scar contracture; in addition, the medication is also intended for treatment of one or more types of skin aging, selected from the following list: skin wrinkles, sagging skin, rough skin, skin thinning and reduction of skin resilience and elasticity because of rupture of dermal tissues or reduction of functions of fibroblast cells, with skin aging being photoaging, and a value of a dose of the basic fibroblast growth factor (bFGF) constituting from 0.1 mcg to 1 mg per 1 cm2 of skin, which represents the treatment target.

EFFECT: inventions ensure significant reduction of wrinkles, improvement of the skin structure, as well as due to an increase of its turgor and an increase of the volume of the subcutaneous adipose cellular tissue.

6 cl, 4 ex, 10 dwg

FIELD: medicine.

SUBSTANCE: what is described is a dressing for treating skin conditions and relieving symptoms of skin conditions accompanying blood protein exudation, or for absorbing blood proteins transuding onto the skin.

EFFECT: using the dressing for clearance of waste proteins secreted onto the skin.

8 cl, 22 dwg, 7 ex

Burn ointment // 2523551

FIELD: medicine.

SUBSTANCE: ointment contains biologically active substances which are Apis mellifera in an amount of 21-23 wt %, St. John's wort oil in an amount of 12-14 wt %, propolis in an amount of 10-12 wt % and wax in an amount of 7-9 wt %, as well as Vaselin and lanolin as the ointment base.

EFFECT: invention accelerates cell regeneration processes considerably due to a synergetic action of the ingredients.

7 ex

FIELD: medicine.

SUBSTANCE: dressing represents a knitted mesh fabric coated with a composition of a biocompatible film-forming polymer of polyvinyl pyrrylidone and drug preparations: iodine, novociane, carboxymethyl cellulose sodium salt, of the following formulation (mg/cm2): iodine 0.0282±20%; polyvinyl pyrrylidone (Mr 20000) 1.2±20%; novociane 0.426±20%; carboxymethyl cellulose sodium salt 1.6-1.9.

EFFECT: using the wipe provides antimicrobial, antiseptic, disinfecting, antifungal and antiprotozoal action ensured by the fact that a polyvinyl pyrrylidone matrix retains iodine in the wipe and promotes its release on the skin.

FIELD: medicine.

SUBSTANCE: postoperative period involves tamponage with Coletex-AGGDM wet tissue within middle nasal passages. The tamponage area is exposed to laser light in the infrared band at a wave length 0.95 mcm at the output power of 2-3 mWt for 4-5 min. After the exposure, the tissue is left for one day. The following procedures are performed with the tissues placed in the middle nasal passage within a natural fistula and on a mucous membrane of a hard palate in a projection of a maxillary sinus bottom. The tamponage area and skin in the projection of the maxillary sinus within an anterior sinus wall are exposed. 2-3 procedures are performed at the output power of 5-7 mWt for 7-10 min for one field. 4-6 procedures are performed at the power of 15-20 mWt for 3-10 min for each field. After the exposure is terminated after each procedure, the endonasal tissue is left for 6-8 hours.

EFFECT: method enables providing higher clinical effectiveness by antibacterial, antiseptic, anti-oedematous effects, recovering the ciliary transport function without injuring the ciliated epithelium; eliminating the postoperative complications, such as sinus bleeding and cicatrical deformity of the mucous membrane.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a copper-bearing cellulosic material possessing the fungicidal, bactericidal and deodorant properties, containing a cellulose matrix coated with copper particles prepared by chemical reduction of copper ions absorbed in the cellulose matrix, differing by the fact that the copper ions absorbed in the cellulose matrix are reduced in micelle solution of a cationic surfactant; the material contains copper and copper oxide nanoparticles with the size of 5-19 nm and has a composition as follows, wt %: cellulose matrix 99.5-98.0, copper nanoparticles 0.5-2.0.

EFFECT: said materials can find application in manufacturing sanitary products.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine. What is described is a method for preparing a transdermal therapeutic system based on poly(lactic-co-glycolic acid) involving dissolving poly lactide-co-glycolide and a pharmaceutically active substance in an organic solvent, mixing the prepared solution until dissolved completely, hot air drying until dry completely and having a constant weight to prepare a film, cutting the film into sections and packing, with the relation of lactide and glycolide varying within the range of 95:5 to 5:95 (versions).

EFFECT: preparing the transdermal therapeutic system based on poly(lactic-co-glycolic acid) that is biodegradable.

33 cl, 1 dwg, 3 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, enabling preparing a biologically active preparation of autoblood for enhancing neogenesis processes. The presented technique involves sampling whole blood, centrifuging, selecting a middle layer of plasma so that to avoid the erythrocyte ingress. The centrifuged platelet concentrate is frozen in a cold room at temperature below minus 1 C°, dried for at least three minutes within the temperature range of 2 C° to 52 C°; the lyophilisate is sterilised before use.

EFFECT: technique of platelet-rich plasma lyophilisation enables preserving the TGF PDGF VEGF factor viability min 1,5 months from the moment of blood sampling.

1 tbl

FIELD: medicine.

SUBSTANCE: what is presented is a boric coating containing a barrier material and an adhesive material. The barrier material and adhesive material are applicable for combined or sequential postoperative application on the mucosal tissue. Such application provides a multilayer film dressing containing a layer of the above barrier material and a layer of the above adhesive material contacting with the barrier material and mucosal tissue. The dressing is left unmoved in place for 48 hours after the postoperative application of the multilayer film on the mucosal tissue. The dressing is absorbed for 14 days. The multilayer film dressing has an external rim surrounding a tonsil bed and a concave centre shaped after the tonsil bed.

EFFECT: reducing or eliminating pain sensations following the mucosal operations, including tonsilectomy, adenoidectomy or other pharyngeal operations.

19 cl, 17 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically to dressings used in general surgery, traumatology, obstetrics, gynaecology, proctology, dentistry for closure and healing of wounds (including post-operative), bed-sores, ulcers, burns, complicated purulent and putrid infections with an evident purulo-necrotic layer. A wound and burn closure and healing dressing containing a wound or burn facing therapeutic layer consisting of a therapeutic and sorption agent that is a layer of paste-like gel of iron or aluminium gel with added graphite carbon at 1 g of the additive per 100 ml of the gel, of the thickness of 0.5 cm providing a sorption ability not less than 10 g/g.

EFFECT: preparing the wound and burn dressing possessing high antimicrobial activity and analgesic characteristics, improved sorption ability and atraumatic properties.

7 tbl, 23 dwg

Wound tissue // 2483755

FIELD: medicine.

SUBSTANCE: invention refers to medicine, to preparing a therapeutic and preventing agent for treating radioreactions accompanying the course of radiotherapy. A wound tissue contains a textile fibre-porous material with a viscose component coated with a polymer and a drug preparation introduced therein; the novel is the fact that it is suggested to use the textile material which is made of flax-viscose fibres in ratio of components of flax:viscose 40 - 70 and 60-30, respectively. The fibre-porous material is prepared by needle suturing and has area density 180 g/m2 - 260 g/m2. The coating polymer is sodium alginate, while the drug preparation is introduced in the concentration of 0.25-30 wt %. The drug preparation coating the suggested flax-viscose carrier is presented by poorly soluble preparations of Furaginum, metronidazole, 5-fluoruracil, antioxidant Mexidol, biologically active substances - propolis, sea buckthorn and blackberry extracts.

EFFECT: presented drug preparation has proved itself to be easy to use, enabling higher clinical effectiveness, increasing a prolongation time.

6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a sorption plate containing furacilin, differing by the fact that a process for making it involves using the additional excipient therapeutic powdered Kimmeridge clay (blue) Undorovskaya, chitosan solution, dimethylsulphoxide, glycerol, acetic acid and purified water in the following proportions (wt %): furacilin 0.75 - 1.5; dimethylsulphoxide 2.5 - 5.0; blue clay 7.5 - 8.5; 98% acetic acid 1.5 - 3.0; chitosan 2.5 - 4.5; glycerol (7.5 - 8.5); purified water up to 100.0.

EFFECT: invention provides making sorption plates for ensuring wound-healing, anti-inflammatory action in medical practice and higher sorption activity.

9 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a composition for preparing a polyurethane foam dressing which contains the ingredients in the composition in the following ratio, weight fractions: low-molecular polyesterpolyol No. 1 - 75-90, low-molecular polyesterpolyol No. 2 - 10-25, water - 1.0-2, a foaming agent - 1.0-3.0, an urethane formation catalyst - 0.05-0.3, a co-catalyst - 0.05-0, a foam regulator - 2.0-7.5, a bactericidal additive - 1.0-1.2, aromatic diisocyanate - 30-60.

EFFECT: requiring no additional fixation, the medical dressing is easily applied on a wound surface regardless of a configuration and a size of the injured area, and is formed directly on the patient's wound, providing a sterile surface and an anaesthetic effect; its open porous structure absorbs various wound discharges.

3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of obtaining and production of filtering materials for purification of air of industrial premises based on polymer fibres, possessing antibiotic properties. Synthesis of a polymer on a filtering material in low-temperature glow discharge plasma in adamantane vapours is performed. First, a chamber with the filtering material is vacuumed, argon is supplied and gas discharge purification of material is carried out. After purification the chamber is re-vacuumed and vapours of adamantane are input with further ignition of the glow discharge to obtain a thin coating on the material surface.

EFFECT: invention makes it possible to render antibiotic (antifungal) properties to the surface of the filtering material.

1 ex

Up!